Navigation Links
Drug-Coated Sponges May Limit Catheter Infections
Date:3/24/2009

More than 10% of ICU patients are thought to develop these infections,,,,

TUESDAY, March 24 (HealthDay News) -- Adding a sponge soaked in an antibacterial agent to the dressing around the spot where a catheter is inserted appears to reduce the chances that a potentially deadly infection will develop, French researchers report.

People in intensive care units (ICUs) usually require insertion of a central venous catheter. In the United States, about 80,000 catheter-related infections occur each year among ICU patients, including those caused by MRSA bacteria (methicillin-resistant Staphylococcus aureus). The death rate from these infections can be as high as 11.5 percent, the researchers reported in the study.

"This is an important study," said Dr. Marc Siegel, an associate professor of medicine at New York University School of Medicine in New York City, who was not involved in the research. "The specific use of disinfectant in this way is important in preventing life-threatening infections" and has the potential to dramatically reduce the number of catheter-related infections, he said.

The report is published in the March 25 issue of the Journal of the American Medical Association.

For the study, the research team randomly assigned more than 1,600 ICU patients to have their catheters inserted with sponges soaked in chlorhexidine gluconate, an antibacterial commonly used in mouthwash, or to have standard dressings used on the insertion site. Dressings were changed every three to seven days.

They found that the rate of infections dropped from 1.1 percent among people who'd had standard dressings to 0.5 percent among those with an antibacterial-soaked dressing -- a 61 percent reduction. The researchers estimated that the chlorhexidine gluconate dressings prevented one major infection for every 117 catheters left in place for about 10 days.

Besides reducing infections, use of bacterial-soaked sponges also appeared to require less frequent changing of dressings, the researchers noted.

Bacteria was found on 7.8 percent of the catheters removed after three days, the study found, and on 8.6 percent of the catheters removed after seven days, for a difference of 0.8 percent.

They described this as a modest reduction that "appears safe."

However, one expert remained dubious as to the advisability of leaving dressings on for longer than the standard three days.

"What is extremely important here is that, while the infection rate did not increase with these less-frequent dressing changes, this finding applied only to unsoiled dressings," said Dr. Pascal James Imperato, dean of the graduate program in public health at the State University of New York Downstate Medical Center, New York City.

Because leakage and soiling are very common at catheter insertion sites, it wasn't surprising that the study found that the absolute decrease in dressing changes was modest, Imperato said.

"In other words, in most patients, the dressings need to be changed every three days -- if not more often -- because of leakage and soiling," he said. "Thus the findings of this study have limited practical application."

More information

The U.S. Centers for Disease Control and Prevention have more on protecting patients from infection.



SOURCES: Pascal James Imperato, M.D., M.P.H., dean, distinguished service professor, Graduate Program in Public Health, State University of New York Downstate Medical Center, New York City; Marc Siegel, M.D., associate professor of medicine, New York University School of Medicine, New York City; March 25, 2009, Journal of the American Medical Association


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UT Southwestern researchers find drug-coated stents less risky for heart bypass patients
2. Drug-Coated Stents Reduce Repeat Artery Procedures
3. More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
4. Drug-Coated Stents Still Spark Debate
5. New Drug-Coated Stent Does Well in Early Trial
6. Drug-coated balloon overcomes in-stent restenosis
7. Drug-Coated Balloons Keep Leg Arteries Open: Study
8. Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
9. Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
10. Study Finds Benefits With Drug-Coated Stents
11. Drug-Coated Stents Go Head to Head
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug-Coated Sponges May Limit Catheter Infections
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding ... The following programs will be expanding due to high demand: Master of Business Administration ... will begin this summer. , School of Business Graduate Program Chair Dr. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study ... severe congenital diaphragmatic hernia have better survival rates if surgery is performed early. ... condition where the diaphragm fails to form completely, letting abdominal organs into the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... patented products, announces the Gyrociser, an exercise invention which aids in proper muscle ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
Breaking Medicine Technology: